Indian Pediatrics

, Volume 50, Issue 3, pp 307–313 | Cite as

Propranolol therapy for infantile hemangioma

  • Nivedita Gunturi
  • Sriram Ramgopal
  • Subramanian Balagopal
  • Julius Xavier Scott
Review Article

Abstract

Context

There has been widespread interest surrounding the use of beta-blockers (i.e. propranolol, timolol, nadolol, acebutolol) in the treatment of infantile hemangiomas (IH).

Objective

To review literature evaluating treatment of IH with propranolol.

Evidence Acquisition

We conducted a literature search on PubMed and investigated for case reports, case series, and controlled trials by using search terms including “hemangioma” and “propranolol.”

Results

Data suggest that beta-blockers are efficacious in cutaneous, orbital, subglottic, and hepatic hemangiomas and assist in the resolution of ulcerated hemangiomas. Improvement has also been documented in children with PHACE syndrome. Propranolol produces favorable results in children who do not respond to steroids and with no long-term adverse effects. Propranolol should be administered with caution due to rare but serious side effects including hypoglycemia, wheezing, hypotension, and bradycardia. Additionally, recurrence of lesions following the cessation of treatment has been documented.

Conclusions

Although large-scale randomized controlled trials must be conducted in order to further evaluate the safety and the possible role of propranolol in the treatment of IH, the reviewed literature suggests that propranolol carries promise as a potential replacement for corticosteroids as first-line therapy or as a part of a multimodal approach.

Key words

Beta-blockers Capillary hemangioma Infants PHACE association Propranolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a Research Workshop on Infantile Hemangiomas; 2005 April 7–9; Bethesda, Maryland, USA. Hoboken: Wiley-Blackwell; 2005.Google Scholar
  2. 2.
    Young AZ, Cohen BA, Siegfried EC. Cutaneous Congenital Defects. In: Taeusch HW, Ballard RA, Gleason CA, Avery ME, editors. Avery’s diseases of the newborn. 8th ed. Philadelphia: Elsevier Saunders; 2005. p. 1521–1538.CrossRefGoogle Scholar
  3. 3.
    Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–468.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheng JF, Gole GA, Sullivan TJ. Propranolol in the management of periorbital infantile haemangioma. Clin Experiment Ophthalmol. 2010;38:547–553.PubMedCrossRefGoogle Scholar
  5. 5.
    Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol. 2001;159:2271–2280.PubMedCrossRefGoogle Scholar
  6. 6.
    Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93:2357–2364.PubMedCrossRefGoogle Scholar
  7. 7.
    North PE, Waner M, Mizeracki A, Mihm MC, Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31:11–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358: 2649–2651.PubMedCrossRefGoogle Scholar
  9. 9.
    Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128:e259–e266.PubMedCrossRefGoogle Scholar
  10. 10.
    Bingham MM, Saltzman B, Vo NJ, Perkins JA. Propranolol reduces infantile hemangioma volume and vessel density. Otolaryngol Head Neck Surg. 2012;147:338–344.PubMedCrossRefGoogle Scholar
  11. 11.
    Greenberger S, Bischoff J. Infantile Hemangioma-Mechanism(s) of Drug Action on a Vascular Tumor. Cold Spring Harb Perspect Med. 2011;1:a006460.PubMedGoogle Scholar
  12. 12.
    Egert S, Nguyen N, Schwaiger M. Contribution of alphaadrenergic and beta-adrenergic stimulation to ischemiainduced glucose transporter (GLUT) 4 and GLUT1 translocation in the isolated perfused rat heart. Circ Res. 1999;84:1407–1415.PubMedCrossRefGoogle Scholar
  13. 13.
    Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124:e423–e431.PubMedCrossRefGoogle Scholar
  14. 14.
    Zvulunov A, McCuaig C, Frieden IJ, Mancini AJ, Puttgen KB, Dohil M, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011;28:94–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Bagazgoitia L, Torrelo A, Gutierrez JC, Hernandez-Martin A, Luna P, Gutierrez M, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011;28:108–114.PubMedCrossRefGoogle Scholar
  16. 16.
    Marsciani A, Pericoli R, Alaggio R, Brisigotti M, Vergine G. Massive response of severe infantile hepatic hemangioma to propanolol. Pediatr Blood Cancer. 2010;54:176.PubMedCrossRefGoogle Scholar
  17. 17.
    Mistry N, Tzifa K. Use of propranolol to treat multicentric airway haemangioma. J Laryngol Otol. 2010;124:1329–1332.PubMedCrossRefGoogle Scholar
  18. 18.
    Hermans DJ, van Beynum IM, Schultze Kool LJ, van de Kerkhof PC, Wijnen MH, van der Vleuten CJ. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011;64:833–838.PubMedCrossRefGoogle Scholar
  19. 19.
    Muthamilselvan S, Vinoth PN, Vilvanathan V, Ninan B, Amboiram P, Sai V, et al. Hepatic haemangioma of infancy: role of propranolol. Ann Trop Paediatr. 2010;30:335–338.PubMedCrossRefGoogle Scholar
  20. 20.
    Blatt J, Morrell DS, Buck S, Zdanski C, Gold S, Stavas J, et al. beta-blockers for infantile hemangiomas: a singleinstitution experience. Clin Pediatr (Phila). 2011;50:757–763.CrossRefGoogle Scholar
  21. 21.
    Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011;64:445–451.PubMedCrossRefGoogle Scholar
  22. 22.
    Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147:1371–1376.PubMedCrossRefGoogle Scholar
  23. 23.
    Rossler J, Schill T, Bahr A, Truckenmuller W, Noellke P, Niemeyer CM. Propranolol for proliferating infantile haemangioma is superior to corticosteroid therapy — a retrospective, single centre study. J Eur Acad Dermatol Venereol. 2012;26:1173–1175.PubMedCrossRefGoogle Scholar
  24. 24.
    Schupp CJ, Kleber JB, Gunther P, Holland-Cunz S. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol. 2011;28:640–644.PubMedCrossRefGoogle Scholar
  25. 25.
    Celik A, Tiryaki S, Musayev A, Kismali E, Levent E, Ergun O. Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers. J Drugs Dermatol. 2012;11:808–811.PubMedGoogle Scholar
  26. 26.
    Saint-Jean M, Leaute-Labreze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, Kupfer-Bessaguet I, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011;64:827–832.PubMedCrossRefGoogle Scholar
  27. 27.
    Talaat AA, Elbasiouny MS, Elgendy DS, Elwakil TF. Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. J Pediatr Surg. 2012;47:707–714.PubMedCrossRefGoogle Scholar
  28. 28.
    Bertrand J, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Powell J. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol. 2011;28:649–654.PubMedCrossRefGoogle Scholar
  29. 29.
    Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr. 2010;157:340–342.PubMedCrossRefGoogle Scholar
  30. 30.
    Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011;170:493–501.PubMedCrossRefGoogle Scholar
  31. 31.
    Blanchet C, Nicollas R, Bigorre M, Amedro P, Mondain M. Management of infantile subglottic hemangioma: acebutolol or propranolol? Int J Pediatr Otorhinolaryngol. 2010;74:959–961.PubMedCrossRefGoogle Scholar
  32. 32.
    Vanlander A, Decaluwe W, Vandelanotte M, Van Geet C, Cornette L. Propranolol as a novel treatment for congenital visceral haemangioma. Neonatology. 2010;98:229–231.PubMedCrossRefGoogle Scholar
  33. 33.
    Fulkerson DH, Agim NG, Al-Shamy G, Metry DW, Izaddoost SA, Jea A. Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review. Childs Nerv Syst. 2010;26:1799–1805.PubMedCrossRefGoogle Scholar
  34. 34.
    Haider KM, Plager DA, Neely DE, Eikenberry J, Haggstrom A. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS. 2010;14:251–256.PubMedCrossRefGoogle Scholar
  35. 35.
    Leboulanger N, Cox A, Garabedian EN, Denoyelle F. Infantile haemangioma and beta-blockers in otolaryngology. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128:236–240.PubMedCrossRefGoogle Scholar
  36. 36.
    Hernandez-Martin S, Lopez-Gutierrez JC, Lopez-Fernandez S, Ramirez M, Miguel M, Coya J, et al. Brain Perfusion SPECT in Patients with PHACES Syndrome Under Propranolol Treatment. Eur J Pediatr Surg. 2011.Google Scholar
  37. 37.
    Mohanan S, Besra L, Chandrashekar L, Thappa DM. Excellent response of infantile hemangioma associated with PHACES syndrome to propranolol. Indian J Dermatol Venereol Leprol. 2012;78:114–115.PubMedCrossRefGoogle Scholar
  38. 38.
    Chai Q, Chen WL, Huang ZQ, Zhang DM, Fan S, Wang L. Preliminary Experiences in Treating Infantile Hemangioma With Propranolol. Ann Plast Surg. 2011.Google Scholar
  39. 39.
    Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146:775–778.PubMedCrossRefGoogle Scholar
  40. 40.
    Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2012;29:154–159.PubMedCrossRefGoogle Scholar
  41. 41.
    Moehrle M, Leaute-Labreze C, Schmidt V, Rocken M, Poets CF, Goelz R. Topical Timolol for Small Hemangiomas of Infancy. Pediatr Dermatol. 2012.Google Scholar
  42. 42.
    Erbay A, Sarialioglu F, Malbora B, Yildirim SV, Varan B, Tarcan A, et al. Propranolol for infantile hemangiomas: a preliminary report on efficacy and safety in very low birth weight infants. Turk J Pediatr. 2010;52:450–456.PubMedGoogle Scholar
  43. 43.
    Ye XX, Jin YB, Lin XX, Ma G, Chen XD, Qiu YJ, et al. [Topical timolol in the treatment of periocular superficial infantile hemangiomas: a prospective study]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2012;28:161–164.PubMedGoogle Scholar
  44. 44.
    Koay AC, Choo MM, Nathan AM, Omar A, Lim CT. Combined low-dose oral propranolol and oral prednisolone as first-line treatment in periocular infantile hemangiomas. J Ocul Pharmacol Ther. 2011;27:309–311.PubMedCrossRefGoogle Scholar
  45. 45.
    Rosbe KW, Suh KY, Meyer AK, Maguiness SM, Frieden IJ. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg. 2010;136:658–665.PubMedCrossRefGoogle Scholar
  46. 46.
    Nunn A, Shah U, Ford J. Giving propranolol tablets to infants with hemangiomas. J Paediatr Child Health. 2011;47:927.PubMedCrossRefGoogle Scholar
  47. 47.
    Awadein A, Fakhry MA. Evaluation of intralesional propranolol for periocular capillary hemangioma. Clin Ophthalmol. 2011;5:1135–1140.PubMedCrossRefGoogle Scholar
  48. 48.
    Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–614.PubMedCrossRefGoogle Scholar
  49. 49.
    Qin ZP, Liu XJ, Li KL, Zhou Q, Yang XJ, Zheng JW. [Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety]. Zhonghua Yi Xue Za Zhi. 2009;89:3130–3134.PubMedGoogle Scholar
  50. 50.
    Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120:676–681.PubMedCrossRefGoogle Scholar

Copyright information

© Indian Academy of Pediatrics 2013

Authors and Affiliations

  • Nivedita Gunturi
    • 1
    • 2
  • Sriram Ramgopal
    • 4
    • 2
  • Subramanian Balagopal
    • 1
    • 2
  • Julius Xavier Scott
    • 3
    • 2
    • 5
  1. 1.Departments of PediatricsSri Ramachandra UniversityChennaiIndia
  2. 2.Departments of Pediatric SurgerySri Ramachandra UniversityChennaiIndia
  3. 3.Departments of Pediatric Hemato-OncologySri Ramachandra UniversityChennaiIndia
  4. 4.Department of NeurologyBoston Children’s Hospital, BostonMassachusettsUSA
  5. 5.Pediatric Hemato-OncologySri Ramachandra UniversityChennaiIndia

Personalised recommendations